Monday, November 14, 2016
- 9:00AM-11:00AM
-
Abstract Number: 1617
Treatment with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, Improves Fatigue and Health-Related Physical and Emotional Well Being in Patients with Active Rheumatoid Arthritis Refractory to Conventional or Biologic Therapy: Results of 2 Global, Placebo-Controlled, Phase 3 Trials
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1650
Treatment with Tofacitinib Inhibits Human Naive B Lymphocyte Development and Function in Vitro
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1505
Trends in Hospitalizations for Infections in US Patients with Rheumatoid Arthritis, 1993-2013
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1365
Trends in Medication Usage in Patients with Juvenile Dermatomyositis
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome- 9:00AM-11:00AM
-
Abstract Number: 1510
Trends in the Occurrence of Malignancy in Japanese Patients with Rheumatoid Arthritis Based on the Institute of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort during a 14-Year Observation Period
Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications- 9:00AM-11:00AM
-
Abstract Number: 1675
Triptolide Inhibits Th17 Differentation By JAK2/STAT3 Signal Pathway in Inflammation of Ankylosing Spondylitis
Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I- 9:00AM-11:00AM
-
Abstract Number: 1129
Tumor Necrosis Factor Receptor 2 Is Crucial for Regulatory T Cells Activity with Consequences in a Model of Chronic Inflammation and in Anti-TNF Treated Rheumatoid Arthritis
Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I- 9:00AM-11:00AM
-
Abstract Number: 1669
Type 3 Innate Lymphoid Cells Numbers in Peripheral Blood Predict Ustekinumab (Stelara) Therapy Responsiveness in Psoriatic Disease Cases with Subclinical Imaging Enthesopathy
Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I- 9:00AM-11:00AM
-
Abstract Number: 1340
Type and Frequency of Immune-Related Adverse Reactions in Patients Treated with Pembrolizumab (Keytruda), a Monoclonal Antibody Directed Against PD-1, in Advanced Melanoma at a Single Institution
Miscellaneous Rheumatic and Inflammatory Diseases - Poster II- 9:00AM-11:00AM
-
Abstract Number: 1827
Type I IFN Signature Low and High SLE Subjects with Moderate to Severe Disease Activity Have Distinct Gene Expression Signatures of Immunologic Pathways and Cell Types
Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster I- 9:00AM-11:00AM
-
Abstract Number: 1082
Type I/II Interferon Commits to Abnormal Expression of Chemokine Receptor on B Cells in Patients with Systemic Lupus Erythematosus
B Cell Biology and Targets in Autoimmune Disease - Poster I: SLE and Sjögren's- 9:00AM-11:00AM
-
Abstract Number: 1265
Ultra-High Field MRI and Biomechanical Investigation of Vertebral Bone Microarchitecture
Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI- 9:00AM-11:00AM
-
Abstract Number: 1401
Ultrasonography of Major Salivary Glands in Juvenile SjöGren’s Syndrome − Preliminary Findings in a Multi-Center Study
Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome- 9:00AM-11:00AM
-
Abstract Number: 1354
Ultrasound Verified Inflammation and Structural Abnormalities in Patients with Hemochromatosis with and without Associated Arthropathy